BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32559147)

  • 1. The role of microRNA in cisplatin resistance or sensitivity.
    Wang S; Li MY; Liu Y; Vlantis AC; Chan JY; Xue L; Hu BG; Yang S; Chen MX; Zhou S; Guo W; Zeng X; Qiu S; van Hasselt CA; Tong MC; Chen GG
    Expert Opin Ther Targets; 2020 Sep; 24(9):885-897. PubMed ID: 32559147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
    Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD.
    Zhu M; Zhou X; Du Y; Huang Z; Zhu J; Xu J; Cheng G; Shu Y; Liu P; Zhu W; Wang T
    Mol Med Rep; 2016 Aug; 14(2):1742-50. PubMed ID: 27357419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
    Samuel P; Pink RC; Brooks SA; Carter DR
    Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
    Yu JL; Gao X
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
    Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
    Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells.
    Shi S; Huang X; Ma X; Zhu X; Zhang Q
    PLoS One; 2020; 15(5):e0225290. PubMed ID: 32369495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
    Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
    Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
    Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
    Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
    Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
    Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
    Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
    Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells.
    Bozok Çetintaş V; Tetik Vardarlı A; Düzgün Z; Tezcanlı Kaymaz B; Açıkgöz E; Aktuğ H; Kosova Can B; Gündüz C; Eroğlu Z
    Tumour Biol; 2016 Feb; 37(2):1739-51. PubMed ID: 26314859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.